Coronary artery bypass graft surgery devices are used in the surgery to improve blood flow to the obstructed coronary artery. Surgeons use these devices to treat people who have severe coronary heart disease. GlobalData’s report provides comprehensive information about the coronary artery bypass graft surgery devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The report also provides key information and data related to major pipeline products which include product description, licensing and collaboration details, and other developmental activities such as pipeline territories, regulatory paths, and estimated approval dates. The report contains key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major coronary artery bypass graft surgery devices pipeline products.
What is the territory outlook in the coronary artery bypass graft surgery devices pipeline products market?
The US accounts for the highest number of pipeline products in the market followed by Europe, Israel, and Canada.
Coronary artery bypass graft surgery devices pipeline products to market, by regions
For more regional insights, download a free report sample
What are the segments in the coronary artery bypass graft surgery devices pipeline products market?
The key segments in the coronary artery bypass graft surgery devices pipeline products market are based on stages of development, regulatory path, estimated approval date, and ongoing clinical trials. As of December 2021, most of the pipeline products in the market are in the inactive stage. Early development, pre-clinical and clinical account for less than 5 products in the market each. The maximum number of pipeline products will be approved in 2024. In 2028, 2 products in the pipelines will be approved by the first quarter of the year.
Coronary artery bypass graft surgery devices pipeline products market, by stages of development
For more segment insights, download a free report sample
Which are the major companies in the coronary artery bypass graft surgery devices pipeline products market?
The key companies in the coronary artery bypass graft surgery devices pipeline products market are AdvanSource Biomaterials Corporation, ArtiFex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc, Cardious Inc, Centre Hospitalier Universitaire de Nice, Coromedic Ltd., Cytograft Tissue Engineering Inc (Inactive), Elana bv, enVVeno Medical Corp, Graft-Loc Inc., H. Lee Moffitt Cancer Center & Research Institute Inc, iiTech BV, McGill University, and Medical 21 Inc.
Company Overview
AdvanSource Biomaterials Corporation: It develops polymer materials, used in the design and development of medical devices. The company primarily offers products such as chronoFlex AL, chornoFlex AR, Chrono sil, hydroMed, and polyBlend. AdvanSource’s services include customized materials, product extension, custom solutions, and project management. Its biomaterial products are used in devices that are designed for treating a range of anatomical sites and disease states. The company has its presence in the US, Canada, China, India, and Egypt. AdvanSource is headquartered in Wilmington, Massachusetts, the US.
ArtiFex Medical GmbH: ArtiFex Medical GmbH (ArtiFex) develops grafts for cardiovascular bypasses and is headquartered in Vienna, Austria.
Axcelon Biopolymers Corp: They are an innovative biomaterials company focused on leveraging its unique bacterial nanocellulose platform technology to develop high-value products for wound care, medical devices, tissue engineering, and industrial applications. The company is in London, Ontario, Canada.
CardioPolymers Inc: The company develops biocompatible polymer implant therapies. It helps to treat chronic heart failure, mitral valve regurgitation, and postoperative atrial fibrillation. It is headquartered in Laguna Hills, California.
Cardious Inc: It is a medical device company that offers valve bypass graft systems. The company offers minimally invasive heart valve therapies. It provides implant and associated tools needed to relieve aortic valve disease. Cardious’ proprietary product aortic valve bypass graft system is a minimally invasive alternative to traditional aortic valve replacement therapy. The company’s valve bypass graft systems are used as a beating heart alternative to traditional aortic valve replacement therapy. It caters to cardiac surgeons, hospitals, and medical centers. The company markets its products across the US. Cardious is headquartered in Northfield, Minnesota, the US.
Coronary artery bypass graft surgery devices pipeline products market, by key players
To know more about key players, download a free report sample
Market report scope
Key countries | The US, Europe, Israel, and Canada
|
Key stages of development | Early Development, Pre-clinical, Clinical, and Inactive |
Key companies | AdvanSource Biomaterials Corporation, ArtiFex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc, Cardious Inc, Centre Hospitalier Universitaire de Nice, Coromedic Ltd., Cytograft Tissue Engineering Inc (Inactive), Elana bv, enVVeno Medical Corp, Graft-Loc Inc., H. Lee Moffitt Cancer Center & Research Institute Inc, iiTech BV, McGill University, and Medical 21 Inc |
This report provides an in-depth analysis of:
- Coronary artery bypass graft surgery devices under development
- Details of major pipeline products, which includes, product description, licensing and collaboration details, and other developmental activities
- Major players involved in the development of coronary artery bypass graft surgery devices and lists all their pipeline projects
- Pipeline products based on various stages of development ranging from early development to approved/issued stage
- Key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
- Formulation of significant competitor information, analysis, and insights to improve R&D strategies
- Identification of emerging players with potentially strong product portfolios and creating effective counter-strategies to gain a competitive advantage
- Identification and understanding of important and diverse types of coronary artery bypass graft surgery devices under development
- Development of market-entry and market expansion strategies
- Planning mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory, and estimated launch date
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key countries in the coronary artery bypass graft surgery devices pipeline products market are the US, Europe, Israel, and Canada.
The key stages of development in this market are early development, pre-clinical, clinical, and inactive.
Key companies in the coronary artery bypass graft surgery devices pipeline products market are AdvanSource Biomaterials Corporation, ArtiFex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc, Cardious Inc, Centre Hospitalier Universitaire de Nice, Coromedic Ltd., Cytograft Tissue Engineering Inc (Inactive), Elana bv, enVVeno Medical Corp, Graft-Loc Inc., H. Lee Moffitt Cancer Center & Research Institute Inc, iiTech BV, McGill University, and Medical 21 Inc.